Compare Illumina, Inc. (ILMN) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Vanguard S&P 500 ETF — how do they compare? Illumina, Inc. trades at $265.01 (market cap $39.95B), while Vanguard S&P 500 ETF trades at $713.9 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 45.1× Illumina, Inc.'s market cap, and Vanguard S&P 500 ETF is trading nearer its 52-week high, Illumina, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Vanguard S&P 500 ETF for 55 Days on average.
| ILMN | VOO | |
|---|---|---|
Market Cap | $39.95B | $1.80T |
Volume | 3,169,503 | 4,722,271 |
Sector | Health | Broad Market / Factor |
52-Week High | $293.69 | $716.17 |
52-Week Low | $91.00 | $580.93 |
Typical Hold Time | 83 Days | 55 Days |
Enterprise Value | $41.31B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
VOO trades at $714.42, down 0.24% with a mild bearish daily move. Technical indicators show a bullish moving average signal but neutral oscillators, with RSI at 75.83 suggesting potential overbought conditions. Recent news highlights the ETF's role in long-term wealth building amid expectations of slowing S&P 500 profit growth from 35% to 15% in 2027. Short interest increased 46.9% in September, indicating growing bearish bets.
The outlook remains cautiously optimistic given VOO's diversified exposure to the S&P 500, though elevated RSI and rising short interest signal near-term pressure. Key risks include macroeconomic headwinds from Fed rate hikes and projected earnings slowdown. The ETF continues to be favored for recession resilience and long-term dollar-cost averaging strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
